Bacteria, particularly E. coli, are the most common expression systems for recombinant proteins. They offer rapid growth, easy manipulation, and high yields. However, E. coli lacks the machinery for post-translational modifications found in eukaryotic cells.

Applications

• Ideal for producing large quantities of proteins for research purposes.
• Suitable for proteins that do not require glycosylation or complex folding.
• Common in industrial enzyme production, such as proteases and polymerases.

Recent studies have highlighted the potential of using E. coli as an expression system for producing therapeutic proteins. Researchers have developed strategies to overcome the limitations of E. coli, such as codon optimization, chaperone co-expression, and periplasmic secretion, allowing for the production of complex proteins with improved solubility and activity. One notable example is the use of E. coli in the production of insulin. By expressing the human insulin gene in E. coli, researchers have been able to produce large quantities of this vital hormone, making it more accessible and affordable for patients with diabetes.

Moreover, E. coli has been employed in the production of vaccines. By expressing antigenic proteins from pathogens, E. coli can be used as a platform for developing recombinant vaccines, which are safer and more stable than traditional vaccines. In the field of industrial enzymes, E. coli continues to be a preferred expression system. For instance, the production of Taq polymerase, a crucial enzyme used in PCR (Polymerase Chain Reaction), relies heavily on E. coli expression systems. This has made Taq polymerase more widely available and cost-effective for researchers and diagnostic laboratories.